US Patent

US10786518 — Compositions and methods of treating HIV

Method of Use · Assigned to Janssen Sciences Ireland ULC · Expires 2038-07-19 · 12y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods of treating HIV in subjects using a once-daily dosage form containing darunavir, cobicistat, emtricitabine, and a tenofovir prodrug.

USPTO Abstract

The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.

Drugs covered by this patent

Tybost (COBICISTAT) · Gilead Sciences

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2978`	—	Tybost

Patent Metadata

Patent number: US10786518
Jurisdiction: US
Classification: Method of Use
Expires: 2038-07-19
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Sciences Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.